Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | C1R | P00736 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.31 |
| ▸ | CLK1 | P49759 | 2/20 | 0.31 |
| ▸ | CLK2 | P49760 | 2/20 | 0.31 |
| ▸ | CLK3 | P49761 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 3/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241911 | 1.00 | CISD1 (0.38) | CISD1ENPP2CHRM4ALOX5MEN1 | |
| SCHEMBL4241809 | 0.92 | ENPP2 (0.37) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4241818 | 0.92 | ENPP2 (0.37) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4240636 | 0.90 | ENPP2 (0.36) | CISD1ENPP2CHRM4ALOX5MEN1 | |
| SCHEMBL4240631 | 0.90 | ENPP2 (0.36) | CISD1ENPP2CHRM4ALOX5MEN1 | |
| SCHEMBL4248938 | 0.87 | ENPP2 (0.39) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4248941 | 0.87 | ENPP2 (0.39) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4237434 | 0.87 | CISD1 (0.36) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4237426 | 0.87 | CISD1 (0.36) | CISD1ENPP2ALOX5MEN1KMT2A | |
| SCHEMBL4238325 | 0.82 | ENPP2 (0.37) | CISD1ENPP2ALOX5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | claimed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | claimed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| EP-1718642-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082901-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | CISD1 2650/4885ENPP2 1265/4885CHRM4 4454/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | CISD1 4327/4885ENPP2 562/4885CHRM4 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.